Toni Weinschenk,Oliver Schoor,Claudia Trautwein,Norbert Hilf,Steffen Walter,Harpreet Singh
申请号：
US15638806
公开号：
US09993540B2
申请日:
2017.06.30
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.
